Phaseline

Companies › Paradigm Therapeutics

Paradigm Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SD-101 Dermal Cream (6%)
Allantoin, a diureide glyoxylic acid derivative promoting wound healing and skin barrier f
–Phase 3Epidermolysis Bullosa (EB)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07482787SD-101 Dermal Cream (6%)Phase 3Epidermolysis Bullosa (EB)OtherMay 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.